DDInter927 DDInter500
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides. Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women. It further received additional indication approval to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September 2011 and in men with osteoporosis at high risk for fracture in September 2012.
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Durvalumab
Denosumab {u} may lead to a major life threatening interaction when taken with {v} Etelcalcetide
Denosumab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Denosumab may lead to a major life threatening interaction when taken with Etelcalcetide
Denosumab may lead to a major life threatening interaction when taken with Cladribine